SLNO Company Profile and Key Details

SLNO has shown mixed momentum, gaining 5.27% over the past week and -33.21% over the past quarter, though year-to-date performance is down -5.55%. Short-term trend indicators are bullishly aligned (SMA20 -4.74%, SMA50 -11.92%, SMA200 -38.96%). The stock’s 14-day RSI is 41.02 (neutral), while the ATR of 2.62 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -57.83% below its high and over 3.87% above its low. Average 10-day trading volume of 1.72 million shares is slightly above the 3-month average of 1.49 million, indicating heightened recent market interest.

Soleno Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $103.54. This means the shares are trading below this model’s fair value.

Soleno Therapeutics, Inc. has 53.15 million shares outstanding. The public float is 44.87 million shares, elevated short interest at 13.55% of float. This equals 6.31 million shares. The short ratio is 4.15 days. Institutional investors hold 127.32% of the float. Insiders own 1.84%. Vivo Opportunity, LLC holds 4.46 million shares, Carlyle Group Inc. has 1.78 million shares and Anish Bhatnagar has 577.08 thousand shares.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) closed at $39.06 USD, losing -$0.01 (-0.03%) from the previous close of $39.07. The stock is currently mid-range between its 52-week high and low $32.63 and $90.32. With a market capitalization of about $2.10 billion, Soleno Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-3.18). Key stats such as the average daily volume over the past year has been around 1.51 million shares, in line with its 52-week average. Headquartered in Redwood City, CA, Soleno Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Anish Bhatnagar, the company employs approximately 115 people and listed since November 13, 2014. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Soleno Therapeutics, Inc. generated EPS of -$1.84 over the past year. Five-year average earnings growth is 20.19%. The latest quarter delivered EPS of $0.47. The next quarter is forecast at $0.75. Next year's EPS is expected at $51.37. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $123.00 to $70.00. The high target offers 214.9% upside. The low target suggests 79.21% downside. The mean target is $104.40. This offers 167.28% upside. Soleno Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 717.39%. The prior quarter beat by -83.02%. Over the last six quarters, Apple has recorded several small beats. These include -9.52% in August 07, 2024.

Soleno Therapeutics, Inc. trades at a P/E ratio of 99.86, slightly above the S&P 500 average, with a price-to-sales ratio of 11.07 and a price-to-book ratio of 4.63 trading at moderately above to book value. The P/FCF stands at 44.92, also below market averages.

Our AI price prediction model suggests that Soleno Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.5%, with price expected at $36.91 by March 13, 2026, within a range of $35.27 to $38.41 3-Month Outlook: Projected rise of 58.37%, reaching $61.86 by May 28, 2026, with a range of $59.45 to $64.11. 1-Year Outlook: Projected gain of 42.06%, with price at $55.49 by February 26, 2027, within a range of $50.68 to $59.83.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares are flat -5.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Soleno Therapeutics, Inc. trading at a premium to the broader market with a P/E of 99.86. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $72.10, suggesting 84.59% upside. Our AI forecast model points to short-term weakness (-5.5% over two weeks), a medium-term rise (58.37% over three months), and a longer-term gain (42.06% over one year), with expected trading ranges indicating moderate volatility.